Panu Mikkonen appointed as Chief Financial Officer of Bioretec
Bioretec Ltd | Company announcement | 5 August 2026 at 4:00 p.m. EEST
Bioretec Ltd, a pioneer in absorbable orthopedic implants, appoints Panu Mikkonen (M.Sc. Econ) as Chief Financial Officer, effective 6 October 2026. In this role, Mikkonen will report to Chief Executive Officer Sarah van Hellenberg Hubar-Fisher and will join the company's management team.
Panu Mikkonen brings nearly 30 years of experience in finance, business controlling, corporate development, and strategic leadership across international organizations. Most recently, he has served as CFO of BPW Kraatz Group, where his responsibilities have included finance and IT operations in Finland and the Baltic states, while acting as a strategic partner to the management and the Board. During his career, Mikkonen has also held senior finance leadership roles at Atoy Group and Nordcloud Group.
Mikkonen holds a master's degree in economics and business administration (accounting) from the Helsinki School of Economics. In his new role, he will oversee all financial operations, including financial planning, reporting, treasury, compliance, and investor relations, while supporting Bioretec's continued international growth and long-term value creation.
"I am excited to join Bioretec at such an important stage of the company's development. Bioretec has a unique position in the global orthopedic market, and I look forward to working with the team to support the company's growth, strengthen its financial foundation, and create long-term value for patients, customers, and shareholders," says Mikkonen.
"We are delighted to welcome Panu to Bioretec. He brings extensive experience in international finance leadership, business transformation, and value creation, which will be highly valuable as we continue to execute our growth strategy and expand globally. Panu joins us at an exciting stage in Bioretec's journey, and we look forward to his contributions in helping us achieve our strategic objectives," says CEO Sarah van Hellenberg Hubar-Fisher.
Further enquiries
Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736
Certified Adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com